Orient Europharma Co Ltd (4120) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orient Europharma Co Ltd (4120) has a cash flow conversion efficiency ratio of -0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.84 Million ≈ $-4.97 Million USD) by net assets (NT$7.89 Billion ≈ $248.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4120 net asset quality index to measure how much of total assets are equity-financed.
Orient Europharma Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Orient Europharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4120 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Orient Europharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orient Europharma Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
0.080x |
|
Gunsynd PLC
LSE:GUN
|
-0.112x |
|
LungLife AI Inc
LSE:LLAI
|
-0.245x |
|
Endor AG
MU:E2N
|
691.016x |
|
Rosslyn Data Technologies plc
LSE:RDT
|
3.777x |
|
Distil Plc
LSE:DIS
|
-0.129x |
|
CRESTVIEW EXPLORATION INC
F:CE7
|
N/A |
|
SRAX Inc
NASDAQ:SRAX
|
0.394x |
Annual Cash Flow Conversion Efficiency for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Orient Europharma Co Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Orient Europharma Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.82 Billion ≈ $183.50 Million |
NT$-121.11 Million ≈ $-3.82 Million |
-0.021x | -233.83% |
| 2023-12-31 | NT$4.16 Billion ≈ $131.14 Million |
NT$64.67 Million ≈ $2.04 Million |
0.016x | +124.46% |
| 2022-12-31 | NT$3.44 Billion ≈ $108.50 Million |
NT$-218.75 Million ≈ $-6.89 Million |
-0.064x | -382.48% |
| 2021-12-31 | NT$3.45 Billion ≈ $108.79 Million |
NT$77.65 Million ≈ $2.45 Million |
0.022x | -85.57% |
| 2020-12-31 | NT$3.91 Billion ≈ $123.03 Million |
NT$608.55 Million ≈ $19.17 Million |
0.156x | +161.25% |
| 2019-12-31 | NT$3.81 Billion ≈ $120.09 Million |
NT$227.37 Million ≈ $7.16 Million |
0.060x | +6.82% |
| 2018-12-31 | NT$4.14 Billion ≈ $130.50 Million |
NT$231.31 Million ≈ $7.29 Million |
0.056x | -61.93% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.11 Million |
NT$601.08 Million ≈ $18.94 Million |
0.147x | +416.37% |
| 2016-12-31 | NT$3.92 Billion ≈ $123.38 Million |
NT$111.24 Million ≈ $3.50 Million |
0.028x | -85.07% |
| 2015-12-31 | NT$3.38 Billion ≈ $106.63 Million |
NT$643.97 Million ≈ $20.29 Million |
0.190x | -- |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more